Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID-19: Daily Top 10 Papers

Breast Cancer

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 108 articles: HTML format

Single Articles

January 2022
1. MA CX, Luo J, Freedman RA, Pluard TJ, et al
   The phase II MutHER study of neratinib alone and in combination with fulvestrant in HER2 mutated, non-amplified metastatic breast cancer.
   Clin Cancer Res. 2022 Jan 19. pii: 1078-0432.CCR-21-3418.
   PubMed     Abstract available
   
   
   
2. GARCIA-SAENZ JA, Martinez-Janez N, Cubedo R, Jerez Y, et al
   Sapanisertib Plus Fulvestrant in Post-Menopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer After Progression on Aromatase Inhibitor.
   Clin Cancer Res. 2022 Jan 3. pii: 1078-0432.CCR-21-2652.
   PubMed     Abstract available
   
   
   December 2021
3. KESTER L, Seinstra D, van Rossum AGJ, Vennin C, et al
   Differential survival and therapy benefit of breast cancer patients are characterized by distinct epithelial and immune cell microenvironments.
   Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-1442.
   PubMed     Abstract available
   
   
   
4. LU YS, Im SA, Colleoni M, Franke F, et al
   Updated Overall Survival of Ribociclib Plus Endocrine Therapy vs Endocrine Therapy Alone in Pre- and Perimenopausal Patients With HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial.
   Clin Cancer Res. 2021 Dec 29. pii: 1078-0432.CCR-21-3032.
   PubMed     Abstract available
   
   
   
5. FITZPATRICK A, Iravani M, Mills A, Childs L, et al
   Assessing CSF ctDNA to improve diagnostic accuracy and therapeutic monitoring in breast cancer leptomeningeal metastasis.
   Clin Cancer Res. 2021 Dec 17. pii: 1078-0432.CCR-21-3017.
   PubMed     Abstract available
   
   
   
6. ROYCE M, Osgood CL, Amatya AK, Fiero MH, et al
   FDA Approval Summary: Margetuximab plus chemotherapy for advanced or metastatic HER2-positive breast cancer.
   Clin Cancer Res. 2021 Dec 16. pii: 1078-0432.CCR-21-3247.
   PubMed     Abstract available
   
   
   
7. DI NOIA V, Pimpinelli F, Renna D, Barberi V, et al
   Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution.
   Clin Cancer Res. 2021;27:6815-6823.
   PubMed     Abstract available
   
   
   
8. SHI Z, Wulfkuhle J, Nowicka M, Gallagher RI, et al
   Functional Mapping of AKT Signaling and Biomarkers of Response From the FAIRLANE Trial of Neoadjuvant Ipatasertib Plus Paclitaxel for Triple-Negative Breast Cancer.
   Clin Cancer Res. 2021 Dec 14. pii: 1078-0432.CCR-21-2498.
   PubMed     Abstract available
   
   
   
9. TAN AR, Wright GS, Thummala AR, Danso MA, et al
   Trilaciclib prior to chemotherapy in patients with metastatic triple-negative breast cancer: final efficacy and subgroup analysis from a randomized phase II study.
   Clin Cancer Res. 2021 Dec 9. pii: 1078-0432.CCR-21-2272.
   PubMed     Abstract available
   
   
   
10. ZHOU Q, Gampenrieder SP, Frantal S, Rinnerthaler G, et al
    Persistence of ctDNA in breast cancer patients during neoadjuvant treatment is a significant predictor of poor tumour response.
    Clin Cancer Res. 2021 Dec 3. pii: 1078-0432.CCR-21-3231.
    PubMed     Abstract available
    
    
    November 2021
11. MOORE HCF, Barlow WE, Somlo G, Gralow JR, et al
    A randomized trial of fulvestrant, everolimus and anastrozole for the front-line treatment of patients with advanced hormone receptor-positive breast cancer, SWOG S1222.
    Clin Cancer Res. 2021 Nov 29. pii: 1078-0432.CCR-21-3131.
    PubMed     Abstract available
    
    
    
12. ZHANG J, Ji D, Cai L, Yao H, et al
    First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study.
    Clin Cancer Res. 2021 Nov 29. pii: 1078-0432.CCR-21-2827.
    PubMed     Abstract available
    
    
    
13. HUA X, Bi XW, Zhao JL, Shi YX, et al
    Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Metastatic Breast Cancer with Hormone Receptor-positive and HER2-positive (SYSUCC-002).
    Clin Cancer Res. 2021 Nov 22. pii: 1078-0432.CCR-21-3435.
    PubMed     Abstract available
    
    
    
14. LLOYD MR, Spring LM, Bardia A, Wander SA, et al
    Mechanisms of Resistance to CDK4/6 Blockade in Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer and Emerging Therapeutic Opportunities.
    Clin Cancer Res. 2021 Nov 1. pii: 1078-0432.CCR-21-2947.
    PubMed     Abstract available
    
    
    October 2021
15. ADAMS S, Othus M, Patel SP, Miller KD, et al
    A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).
    Clin Cancer Res. 2021 Oct 29. pii: 1078-0432.CCR-21-2182.
    PubMed     Abstract available
    
    
    
16. ARORA S, Narayan P, Osgood CL, Wedam S, et al
    U.S. FDA Drug Approvals for Breast Cancer - A Decade in Review.
    Clin Cancer Res. 2021 Oct 28. pii: 1078-0432.CCR-21-2600.
    PubMed     Abstract available
    
    
    
17. DIECI MV, Guarneri V, Tosi A, Bisagni G, et al
    Neoadjuvant chemotherapy and immunotherapy in Luminal B-like breast cancer: results of the phase II GIADA trial.
    Clin Cancer Res. 2021 Oct 19. pii: 1078-0432.CCR-21-2260.
    PubMed     Abstract available
    
    
    
18. SYMMANS WF
    Interpreting the Complex Landscape of Immune-Tumor Interface.
    Clin Cancer Res. 2021;27:5446-5448.
    PubMed     Abstract available
    
    
    
19. VENET D, Rediti M, Maetens M, Fumagalli D, et al
    Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial.
    Clin Cancer Res. 2021;27:5607-5618.
    PubMed     Abstract available
    
    
    
20. DOWSETT M, Kilburn L, Rimawi MF, Osborne CK, et al
    Biomarkers of response and resistance to palbociclib plus letrozole in patients with ER+/HER2- breast cancer.
    Clin Cancer Res. 2021 Oct 13. pii: 1078-0432.CCR-21-1628.
    PubMed     Abstract available
    
    
    
21. ASLEH K, Tu D, Gao D, Bramwell V, et al
    Predictive significance of an optimized panel for basal-like breast cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 phase III clinical trials.
    Clin Cancer Res. 2021 Oct 6. pii: 1078-0432.CCR-21-1942.
    PubMed     Abstract available
    
    
    
22. KUEMMEL S, Campone M, Loirat D, Lopez Lopez R, et al
    A Randomized Phase II Study of Anti-CSF-1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple Negative Breast Cancer.
    Clin Cancer Res. 2021 Oct 6. pii: 1078-0432.CCR-20-3955.
    PubMed     Abstract available
    
    
    September 2021
23. SANCHEZ-GUIXE M, Hierro C, Jimenez J, Viaplana C, et al
    High FGFR1-4 mRNA expression levels correlate with response to selective FGFR inhibitors in breast cancer.
    Clin Cancer Res. 2021 Sep 30. pii: 1078-0432.CCR-21-1810.
    PubMed     Abstract available
    
    
    
24. PIZZAMIGLIO S, Ciniselli CM, Triulzi T, Gargiuli C, et al
    Integrated molecular and immune phenotype of HER2-positive breast cancer and response to neoadjuvant therapy: a NeoALTTO exploratory analysis.
    Clin Cancer Res. 2021 Sep 21. pii: 1078-0432.CCR-21-1600.
    PubMed     Abstract available
    
    
    
25. MARQUEZ-ORTIZ RA, Contreras-Zarate MJ, Tesic V, Alvarez-Eraso KL, et al
    IL13Ralpha2 promotes proliferation and outgrowth of breast cancer brain metastases.
    Clin Cancer Res. 2021 Sep 20. pii: 1078-0432.CCR-21-0361.
    PubMed     Abstract available
    
    
    
26. PUHALLA SL, Dieras V, Arun BK, Kaufman B, et al
    Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover).
    Clin Cancer Res. 2021;27:4983-4993.
    PubMed     Abstract available
    
    
    
27. PAOLETTI C, Barlow WE, Cobain EF, Bergqvist M, et al
    Evaluating Serum Thymidine Kinase 1 in Hormone Receptor Positive Metastatic Breast Cancer Patients Receiving First Line Endocrine Therapy in the SWOG S0226 Trial.
    Clin Cancer Res. 2021 Sep 14. pii: 1078-0432.CCR-21-1562.
    PubMed     Abstract available
    
    
    
28. DE ANGELIS C, Fu X, Cataldo ML, Nardone A, et al
    Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
    Clin Cancer Res. 2021;27:4939.
    PubMed    
    
    
    August 2021
29. VATHIOTIS IA, Moutafi MK, Divakar P, Aung TN, et al
    Alpha-smooth muscle actin expression in the stroma predicts resistance to trastuzumab in patients with early-stage HER2-positive breast cancer.
    Clin Cancer Res. 2021 Aug 31. pii: 1078-0432.CCR-21-2103.
    PubMed     Abstract available
    
    
    
30. JHAVERI K, Juric D, Yap YS, Cresta S, et al
    A Phase I Study of LSZ102, an Oral Selective Estrogen Receptor Degrader, With or Without Ribociclib or Alpelisib, in Patients with Estrogen Receptor-Positive Breast Cancer.
    Clin Cancer Res. 2021 Aug 25. pii: 1078-0432.CCR-21-1095.
    PubMed     Abstract available
    
    
    
31. GUARDIA C, Bianchini G, Arpi-LLucia O, Menendez S, et al
    Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer.
    Clin Cancer Res. 2021 Aug 12. pii: 1078-0432.CCR-20-2915.
    PubMed     Abstract available
    
    
    
32. FILIPITS M, Rudas M, Kainz V, Singer CF, et al
    The OncoMasTR test predicts distant recurrence in estrogen receptor-positive, HER2-negative early-stage breast cancer: A validation study in ABCSG Trial 8.
    Clin Cancer Res. 2021 Aug 11. pii: 1078-0432.CCR-21-1023.
    PubMed     Abstract available
    
    
    
33. SAURA C, Matito J, Oliveira M, Wildiers H, et al
    Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine vs Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer.
    Clin Cancer Res. 2021 Aug 11. pii: 1078-0432.CCR-21-1584.
    PubMed     Abstract available
    
    
    
34. NEVEN P, Johnston SRD, Toi M, Sohn J, et al
    MONARCH 2: subgroup analysis of patients receiving abemaciclib plus fulvestrant as first-line and second-line therapy for HR+, HER2- advanced breast cancer.
    Clin Cancer Res. 2021 Aug 10. pii: 1078-0432.CCR-20-4685.
    PubMed     Abstract available
    
    
    
35. NUNES R, Sella T, Treuner K, Atkinson JM, et al
    Prognostic utility of Breast Cancer Index to stratify distant recurrence risk in invasive lobular carcinoma.
    Clin Cancer Res. 2021 Aug 10. pii: 1078-0432.CCR-21-0733.
    PubMed     Abstract available
    
    
    July 2021
36. GONZALEZ-ERICSSON PI, Wulfkhule JD, Gallagher RI, Sun X, et al
    Tumor-specific major histocompatibility-II expression predicts benefit to anti-PD-1/L1 therapy in patients with HER2-negative primary breast cancer.
    Clin Cancer Res. 2021 Jul 27. pii: 1078-0432.CCR-21-0607.
    PubMed     Abstract available
    
    
    
37. TURNER NC, Balmana J, Poncet C, Goulioti T, et al
    Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study.
    Clin Cancer Res. 2021 Jul 22. pii: 1078-0432.CCR-21-0310.
    PubMed     Abstract available
    
    
    
38. YAM C, Yen EY, Chang JT, Bassett RL, et al
    Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer.
    Clin Cancer Res. 2021 Jul 12. pii: 1078-0432.CCR-21-0144.
    PubMed     Abstract available
    
    
    June 2021
39. KOH SB, Ross K, Isakoff SJ, Melkonjan N, et al
    RASAL2 confers collateral MEK/EGFR dependency in chemoresistant triple-negative breast cancer.
    Clin Cancer Res. 2021 Jun 24. pii: 1078-0432.CCR-21-0714.
    PubMed     Abstract available
    
    
    
40. HE X, Ji J, Dai X, Qdaisat AZ, et al
    Association of cardiovascular disease risk factors with late cardiotoxicity and survival in HER2-positive breast cancer survivors.
    Clin Cancer Res. 2021 Jun 11. pii: 1078-0432.CCR-20-4162.
    PubMed     Abstract available
    
    
    
41. ANWAR M, Chen Q, Ouyang D, Wang S, et al
    Pyrotinib treatment in patients with HER2-positive metastatic breast cancer and brain metastasis: exploratory final analysis of real-world, multicenter data.
    Clin Cancer Res. 2021 Jun 10. pii: 1078-0432.CCR-21-0474.
    PubMed     Abstract available
    
    
    
42. THOMPSON PA, Huang C, Yang J, Wertheim BC, et al
    Sulindac, a non-selective NSAID, reduces breast density in postmenopausal women with breast cancer treated with aromatase inhibitors.
    Clin Cancer Res. 2021 Jun 10. pii: 1078-0432.CCR-21-0732.
    PubMed     Abstract available
    
    
    
43. POTTER DA, Thomas A, Rugo HS
    A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes.
    Clin Cancer Res. 2021 Jun 9. pii: 1078-0432.CCR-21-1133.
    PubMed     Abstract available
    
    
    
44. CARTER JM, Polley MC, Leon-Ferre RA, Sinnwell J, et al
    Characteristics and spatially-defined immune (micro)landscapes of early-stage PD-L1-positive triple-negative breast cancer.
    Clin Cancer Res. 2021 Jun 9. pii: 1078-0432.CCR-21-0343.
    PubMed     Abstract available
    
    
    
45. BAI Y, Cole K, Martinez-Morilla S, Ahmed FS, et al
    An Open Source, Automated Tumor Infiltrating Lymphocyte Algorithm for Prognosis in Triple-Negative Breast Cancer.
    Clin Cancer Res. 2021 Jun 4. pii: 1078-0432.CCR-21-0325.
    PubMed     Abstract available
    
    
    
46. WU AML, Gossa S, Samala R, Chung MA, et al
    Aging and CNS myeloid cell depletion attenuate breast cancer brain metastasis.
    Clin Cancer Res. 2021 Jun 3. pii: 1078-0432.CCR-21-1549.
    PubMed     Abstract available
    
    
    
47. BOUGHEY JC, Suman VJ, Yu J, Santo K, et al
    Patient Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY).
    Clin Cancer Res. 2021 Jun 2. pii: 1078-0432.CCR-21-0641.
    PubMed     Abstract available
    
    
    May 2021
48. SERVETTO A, Kollipara R, Formisano L, Lin CC, et al
    Nuclear FGFR1 regulates gene transcription and promotes antiestrogen resistance in ER+ breast cancer.
    Clin Cancer Res. 2021 May 19. pii: 1078-0432.CCR-20-3905.
    PubMed     Abstract available
    
    
    
49. JHAVERI K, Drago JZ, Shah PD, Wang R, et al
    A Phase I study of alpelisib in combination with trastuzumab and LJM716 in patients with PIK3CA-mutated HER2-positive metastatic breast cancer.
    Clin Cancer Res. 2021 May 4. pii: 1078-0432.CCR-21-0047.
    PubMed     Abstract available
    
    
    April 2021
50. RUGO HS, Huppert L
    Answers are in the Blood: cfDNA to Enhance Precision Medicine for Breast Cancer.
    Clin Cancer Res. 2021 Apr 9. pii: 1078-0432.CCR-21-0353.
    PubMed     Abstract available
    
    
    
51. LIM B, Potter DA, Salkeni MA, Silverman P, et al
    Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer.
    Clin Cancer Res. 2021 Apr 5. pii: 1078-0432.CCR-20-4131.
    PubMed     Abstract available
    
    
    March 2021
52. VERNIERI C, Nichetti F, Lalli L, Moscetti L, et al
    Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET).
    Clin Cancer Res. 2021 Mar 30. pii: 1078-0432.CCR-20-4928.
    PubMed     Abstract available
    
    
    
53. AKCAKANAT A, Zheng X, Cruz Pico CX, Kim T, et al
    Genomic, Transcriptomic and Proteomic Profiling of Metastatic Breast Cancer.
    Clin Cancer Res. 2021 Mar 29. pii: 1078-0432.CCR-20-4048.
    PubMed     Abstract available
    
    
    
54. NARAYAN P, Osgood CL, Singh H, Chiu HJ, et al
    FDA Approval Summary: Fam-trastuzumab deruxtecan-nxki for the treatment of unresectable or metastatic HER2-positive breast cancer.
    Clin Cancer Res. 2021 Mar 22. pii: 1078-0432.CCR-20-4557.
    PubMed     Abstract available
    
    
    
55. LI CI, Zhang Y, Cieslik M, Wu YM, et al
    Cancer cell-intrinsic and immunological phenotypes determine clinical outcomes in basal-like breast cancer.
    Clin Cancer Res. 2021 Mar 22. pii: 1078-0432.CCR-20-3890.
    PubMed     Abstract available
    
    
    
56. TOLANEY SM, Kalinsky K, Kaklamani V, D'Adamo DR, et al
    Eribulin Plus Pembrolizumab in Patients With Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase 1b/2 Study.
    Clin Cancer Res. 2021 Mar 16. pii: 1078-0432.CCR-20-4726.
    PubMed     Abstract available
    
    
    
57. BARDIA A, Hurvitz SA, DeMichele A, Clark AS, et al
    Phase I/II trial of exemestane, ribociclib, and everolimus in women with HR+/HER2- advanced breast cancer after progression on CDK4/6 inhibitors (TRINITI-1).
    Clin Cancer Res. 2021 Mar 15. pii: 1078-0432.CCR-20-2114.
    PubMed     Abstract available
    
    
    
58. TOLANEY SM, Sahebjam S, Rhun EL, Bachelot T, et al
    Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-positive Breast Cancer.
    Clin Cancer Res. 2021;27:1582.
    PubMed    
    
    
    February 2021
59. PASCUAL T, Fernandez-Martinez A, Tanioka M, Dieci MV, et al
    Independent validation of the PAM50-based Chemo-Endocrine Score in hormonal receptor positive HER2-positive breast cancer treated with neoadjuvant therapy.
    Clin Cancer Res. 2021 Feb 25. pii: 1078-0432.CCR-20-4102.
    PubMed     Abstract available
    
    
    
60. SHARMA P, Abramson VG, O'Dea AP, Nye L, et al
    Clinical and biomarker results from phase I/II study of PI3K inhibitor alpelisib plus nab-paclitaxel in HER2-negative metastatic breast cancer.
    Clin Cancer Res. 2021 Feb 18. pii: 1078-0432.CCR-20-4879.
    PubMed     Abstract available
    
    
    
61. SINN BV, Loibl S, Hanusch CA, Zahm DM, et al
    Immune-related gene expression predicts response to neoadjuvant chemotherapy but not additional benefit from PD-L1 inhibition in women with early triple-negative breast cancer.
    Clin Cancer Res. 2021 Feb 16. pii: 1078-0432.CCR-20-3113.
    PubMed     Abstract available
    
    
    
62. EDLUND K, Madjar K, Lebrecht A, Aktas B, et al
    Gene expression-based prediction of neoadjuvant chemotherapy response in early breast cancer: results of the prospective multicenter EXPRESSION trial.
    Clin Cancer Res. 2021 Feb 4. pii: 1078-0432.CCR-20-2662.
    PubMed     Abstract available
    
    
    
63. WANG X, Veeraraghavan J, Liu CC, Cao X, et al
    Therapeutic targeting of nemo-like kinase in primary and acquired endocrine-resistant breast cancer.
    Clin Cancer Res. 2021 Feb 4. pii: 1078-0432.CCR-20-2961.
    PubMed     Abstract available
    
    
    
64. DE ANGELIS C, Fu X, Cataldo ML, Nardone A, et al
    Activation of the interferon signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer.
    Clin Cancer Res. 2021 Feb 3. pii: 1078-0432.CCR-19-4191.
    PubMed     Abstract available
    
    
    
65. LIU CC, Veeraraghavan J, Tan Y, Kim JA, et al
    A Novel Neoplastic Fusion Transcript, RAD51AP1-DYRK4, Confers Sensitivity to the MEK Inhibitor Trametinib in Aggressive Breast Cancers.
    Clin Cancer Res. 2021;27:785-798.
    PubMed     Abstract available
    
    
    January 2021
66. ANGUS L, Deger T, Jager A, Martens JWM, et al
    Detection of aneuploidy in cerebrospinal fluid from patients with breast cancer can improve diagnosis of leptomeningeal metastases.
    Clin Cancer Res. 2021 Jan 29. pii: 1078-0432.CCR-20-3954.
    PubMed     Abstract available
    
    
    
67. VIDULA N, Niemierko A, Malvarosa G, Yuen M, et al
    Tumor tissue- versus plasma-based genotyping for selection of matched therapy and impact on clinical outcomes in patients with metastatic breast cancer.
    Clin Cancer Res. 2021 Jan 27. pii: 1078-0432.CCR-20-3444.
    PubMed     Abstract available
    
    
    
68. PETRONI G, Buque A, Yamazaki T, Bloy N, et al
    Radiotherapy delivered before CDK4/6 inhibitors mediates superior therapeutic effects in ER+ breast cancer.
    Clin Cancer Res. 2021 Jan 25. pii: 1078-0432.CCR-20-3871.
    PubMed     Abstract available
    
    
    
69. ALTOE M, Kalinsky K, Marone A, Kim HK, et al
    Changes in diffuse-optical-tomography images during early stages of neoadjuvant chemotherapy correlate with tumor response in different breast cancer subtypes.
    Clin Cancer Res. 2021 Jan 15. pii: 1078-0432.CCR-20-1108.
    PubMed     Abstract available
    
    
    
70. CLARK AS, Makhlin I, DeMichele A
    Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?
    Clin Cancer Res. 2021;27:371-373.
    PubMed     Abstract available
    
    
    
71. MA L, Gonzalez-Junca A, Zheng Y, Ouyang H, et al
    Inflammation mediates the development of aggressive breast cancer following radiotherapy.
    Clin Cancer Res. 2021 Jan 5. pii: 1078-0432.CCR-20-3215.
    PubMed     Abstract available
    
    
    December 2020
72. COLLIN LJ, Cronin-Fenton D, Ahern TP, Goodman M, et al
    Early discontinuation of endocrine therapy and recurrence of breast cancer among premenopausal women.
    Clin Cancer Res. 2020 Dec 17. pii: 1078-0432.CCR-20-3974.
    PubMed     Abstract available
    
    
    
73. JACOB S, Davis AA, Gerratana L, Velimirovic M, et al
    The use of serial circulating tumor DNA (ctDNA) to detect resistance alterations in progressive metastatic breast cancer.
    Clin Cancer Res. 2020 Dec 15. pii: 1078-0432.CCR-20-1566.
    PubMed     Abstract available
    
    
    
74. GARRIDO-CASTRO AC, Spurr LF, Hughes ME, Li YY, et al
    Genomic characterization of de novo metastatic breast cancer.
    Clin Cancer Res. 2020 Dec 8. pii: 1078-0432.CCR-20-1720.
    PubMed     Abstract available
    
    
    
75. BHATIA S, Palomares MR, Hageman L, Chen Y, et al
    A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at risk for Breast Cancer.
    Clin Cancer Res. 2020 Dec 3. pii: 1078-0432.CCR-20-3609.
    PubMed     Abstract available
    
    
    November 2020
76. KEENAN TE, Li T, Vallius T, Guerriero JL, et al
    Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer (mTNBC).
    Clin Cancer Res. 2020 Nov 30. pii: 1078-0432.CCR-20-3089.
    PubMed     Abstract available
    
    
    
77. SOLIMAN H, Hogue D, Han HS, Mooney B, et al
    A phase 1 trial of talimogene laherparepvec in combination with neoadjuvant chemotherapy for the treatment of non-metastatic triple-negative breast cancer.
    Clin Cancer Res. 2020 Nov 20. pii: 1078-0432.CCR-20-3105.
    PubMed     Abstract available
    
    
    
78. SHARMA P, Kimler BF, O'Dea AP, Nye L, et al
    Randomized phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I-III triple-negative breast cancer (NeoSTOP).
    Clin Cancer Res. 2020 Nov 18. pii: 1078-0432.CCR-20-3646.
    PubMed     Abstract available
    
    
    
79. BALLINGER TJ, Jiang G, Kassem N, Radovich M, et al
    Impact of body mass index (BMI) on presence of ctDNA and disease recurrence after neoadjuvant chemotherapy for triple negative breast cancer: analysis from BRE12-158.
    Clin Cancer Res. 2020 Nov 16. pii: 1078-0432.CCR-20-3341.
    PubMed     Abstract available
    
    
    
80. GAO JJ, Osgood CL, Gong Y, Zhang H, et al
    FDA Approval Summary: Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf injection for subcutaneous use in Patients with HER2-Positive Breast Cancer.
    Clin Cancer Res. 2020 Nov 13. pii: 1078-0432.CCR-20-3474.
    PubMed     Abstract available
    
    
    
81. NARAYAN P, Prowell TM, Gao JJ, Fernandes LL, et al
    FDA Approval Summary: Alpelisib plus fulvestrant for patients with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer.
    Clin Cancer Res. 2020 Nov 9. pii: 1078-0432.CCR-20-3652.
    PubMed     Abstract available
    
    
    
82. WAHBY S, Fashoyin-Aje L, Osgood CL, Cheng J, et al
    FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third Line Treatment of Metastatic Triple-negative Breast Cancer (mTNBC).
    Clin Cancer Res. 2020 Nov 9. pii: 1078-0432.CCR-20-3119.
    PubMed     Abstract available
    
    
    
83. ANDREASSEN MMS, Rodriguez-Soto AE, Conlin CC, Vidic I, et al
    Discrimination of breast cancer from healthy breast tissue using a three-component diffusion-weighted MRI model.
    Clin Cancer Res. 2020 Nov 4. pii: 1078-0432.CCR-20-2017.
    PubMed     Abstract available
    
    
    
84. STENMARK TULLBERG A, Puttonen HAJ, Sjostrom M, Holmberg E, et al
    Immune infiltrate in the primary tumor predicts effect of adjuvant radiotherapy in breast cancer; results from the randomized SweBCG91RT trial.
    Clin Cancer Res. 2020 Nov 4. pii: 1078-0432.CCR-20-3299.
    PubMed     Abstract available
    
    
    October 2020
85. COLLINS DM, Madden SF, Gaynor N, AlSultan D, et al
    Effects of HER family-targeting tyrosine kinase inhibitors on antibody-dependent cell-mediated cytotoxicity in HER2-expressing breast cancer.
    Clin Cancer Res. 2020 Oct 29. pii: 1078-0432.CCR-20-2007.
    PubMed     Abstract available
    
    
    
86. BALLHAUSEN A, Wheler JJ, Karp DD, Piha-Paul SA, et al
    Phase I study of everolimus, letrozole, and trastuzumab in patients with hormone receptor-positive metastatic breast cancer or other solid tumors.
    Clin Cancer Res. 2020 Oct 28. pii: 1078-0432.CCR-20-2878.
    PubMed     Abstract available
    
    
    
87. NOORDHOEK I, Treuner K, Putter H, Zhang Y, et al
    Breast Cancer Index predicts extended endocrine benefit to individualize selection of HR+ early stage breast cancer patients for 10 years of endocrine therapy.
    Clin Cancer Res. 2020 Oct 27. pii: 1078-0432.CCR-20-2737.
    PubMed     Abstract available
    
    
    
88. WAHDAN-ALASWAD RS, Edgerton SM, Salem H, Kim H, et al
    Exogenous Thyroid Hormone is Associated with Shortened Survival and Upregulation of High Risk Gene Expression Profiles in Steroid Receptor Positive Breast Cancers.
    Clin Cancer Res. 2020 Oct 23. pii: 1078-0432.CCR-20-2647.
    PubMed     Abstract available
    
    
    
89. GUERINI-ROCCO E, Gray KP, Fumagalli C, Reforgiato MR, et al
    Genomic aberrations and late recurrence in postmenopausal women with hormone receptor-positive early breast cancer: Results from the SOLE Trial.
    Clin Cancer Res. 2020 Oct 20. pii: 1078-0432.CCR-20-0126.
    PubMed     Abstract available
    
    
    
90. SHAH M, Wedam S, Cheng J, Fiero MH, et al
    FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-Positive Breast Cancer.
    Clin Cancer Res. 2020 Oct 14. pii: 1078-0432.CCR-20-2701.
    PubMed     Abstract available
    
    
    
91. LEE HB, Lee SB, Kim M, Kwon S, et al
    Development and validation of a next-generation sequencing-based multigene assay to predict the prognosis of estrogen receptor-positive, HER2-negative breast cancer.
    Clin Cancer Res. 2020 Oct 7. pii: 1078-0432.CCR-20-2107.
    PubMed     Abstract available
    
    
    
92. SCHROTH W, Buttner FA, Kandabarau S, Hoppe R, et al
    Gene expression signatures of BRCAness and tumor inflammation define subgroups of early-stage hormone receptor-positive breast cancer patients.
    Clin Cancer Res. 2020 Oct 2. pii: 1078-0432.CCR-20-1923.
    PubMed     Abstract available
    
    
    September 2020
93. BARDIA A, Modi S, Oliveira M, Cortes J, et al
    Phase 1b Dose Escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women With HR+, HER2- Advanced Breast Cancer.
    Clin Cancer Res. 2020 Sep 30. pii: 1078-0432.CCR-20-1068.
    PubMed     Abstract available
    
    
    
94. KROP I, Abramson VG, Colleoni M, Traina TA, et al
    A Randomized Placebo-Controlled Phase 2 Trial Evaluating Exemestane With or Without Enzalutamide in Patients With Hormone Receptor-positive Breast Cancer.
    Clin Cancer Res. 2020 Sep 28. pii: 1078-0432.CCR-20-1693.
    PubMed     Abstract available
    
    
    
95. PRAT A, Tsai YH, Pascual T, Pare L, et al
    A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer.
    Clin Cancer Res. 2020 Sep 22. pii: 1078-0432.CCR-20-2793.
    PubMed     Abstract available
    
    
    
96. RICHARD F, Majjaj S, Venet D, Rothe F, et al
    Characterization of stromal tumor-infiltrating lymphocytes and genomic alterations in metastatic lobular breast cancer.
    Clin Cancer Res. 2020 Sep 17. pii: 1078-0432.CCR-20-2268.
    PubMed     Abstract available
    
    
    August 2020
97. AUTIO KA, Klebanoff CA, Schaer DA, Kauh JS, et al
    Immunomodulatory Activity of a Colony-Stimulating Factor-1 Receptor Inhibitor in Patients With Advanced Refractory Breast or Prostate Cancer: A Phase 1 Study.
    Clin Cancer Res. 2020 Aug 26. pii: 1078-0432.CCR-20-0855.
    PubMed     Abstract available
    
    
    July 2020
98. TOLANEY SM, Sahebjam S, Le Rhun E, Bachelot T, et al
    A Phase 2 Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer.
    Clin Cancer Res. 2020 Jul 21. pii: 1078-0432.CCR-20-1764.
    PubMed     Abstract available
    
    
    
99. BRAVACCINI S, Ravaioli S, Tumedei MM, Rocca A, et al
    Atezolizumab Plus Nab-paclitaxel in PD-L1-Positive TNBC-Letter.
    Clin Cancer Res. 2020;26:3892-3893.
    PubMed    
    
    
    June 2020
100. ESSERMAN LJ
     Personalization of Treatment is the Way Forward in Care and Trials.
     Clin Cancer Res. 2020;26:2771-2773.
     PubMed     Abstract available
     
     
     May 2020
101. NARAYAN P, Wahby S, Gao JJ, Amiri-Kordestani L, et al
     FDA Approval Summary: Atezolizumab Plus Paclitaxel Protein-bound for the Treatment of Patients with Advanced or Metastatic TNBC Whose Tumors Express PD-L1.
     Clin Cancer Res. 2020;26:2284-2289.
     PubMed     Abstract available
     
     
     March 2020
102. FERNANDEZ-NOGUEIRA P, Mancino M, Fuster G, Lopez-Plana A, et al
     Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation.
     Clin Cancer Res. 2020;26:1432-1448.
     PubMed     Abstract available
     
     
     February 2020
103. HUTCHINSON KE, Yost SE, Chang CW, Johnson RM, et al
     Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts.
     Clin Cancer Res. 2020;26:657-668.
     PubMed     Abstract available
     
     
     
104. HICKS KC, Knudson KM, Lee KL, Hamilton DH, et al
     Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.
     Clin Cancer Res. 2020;26:704-716.
     PubMed     Abstract available
     
     
     
105. BUUS R, Sestak I, Barron S, Loughman T, et al
     Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study.
     Clin Cancer Res. 2020;26:623-631.
     PubMed     Abstract available
     
     
     January 2020
106. KUMTHEKAR P, Tang SC, Brenner AJ, Kesari S, et al
     ANG1005, a brain penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases.
     Clin Cancer Res. 2020 Jan 22. pii: 1078-0432.CCR-19-3258.
     PubMed     Abstract available
     
     
     
107. 
     Selected Articles from This Issue.
     Clin Cancer Res. 2020;26:323.
     PubMed    
     
     
     September 2019
108. SHEE K, Wells JD, Ung M, Hampsch RA, et al
     A transcriptionally-definable subgroup of triple-negative breast and ovarian cancer samples shows sensitivity to HSP90 inhibition.
     Clin Cancer Res. 2019 Sep 26. pii: 1078-0432.CCR-18-2213.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: